J Korean Diabetes.  2021 Mar;22(1):26-37. 10.4093/jkd.2021.22.1.26.

Diabetes and Stroke

• Noh J

• KMID: 2526177
• DOI: http://doi.org/10.4093/jkd.2021.22.1.26

Abstract

Stroke is one of the major complications of diabetes and increases morbidity and mortality. Hyperglycemia confers increased risk of stroke occurrence. Furthermore, cardiometabolic risk factors such as hypertension and dyslipidemia frequently coexist in patients with diabetes and increase the risk of stroke. Some recent cardiovascular outcome trials of newer anti-diabetic medications have shown beneficial effects on cardiovascular complications. Prevention and improving outcomes of stroke in patients with diabetes requires proper management of hyperglycemia and additional risk factors. This review is an evidence-based approach to the epidemiology, glycemic control, effects of anti-diabetic medications on stoke, and risk factor management for prevention and improving outcomes of stroke for patients with diabetes.

Keyword

Diabetes mellitus; Glycemic control; Risk factors; Stroke

Reference

1. Park JH., Ha KH., Kim BY., Lee JH., Kim DJ. Trends in cardiovascular complications and mortality among patients with diabetes in South Korea. Diabetes Metab J. 2021. 45:120–4.

2. Mulnier HE., Seaman HE., Raleigh VS., Soedamah-Muthu SS., Colhoun HM., Lawrenson RA, et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia. 2006. 49:2859–65.

3. Peters SA., Huxley RR., Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014. 383:1973–80.

4. Ståhl CH., Lind M., Svensson AM., Gudbjörnsdottir S., Mårtensson A., Rosengren A. Glycaemic control and excess risk of ischaemic and haemorrhagic stroke in patients with type 1 diabetes: a cohort study of 33 453 patients. J Intern Med. 2017. 281:261–72.

5. Kim JY., Kang K., Kang J., Koo J., Kim DH., Kim BJ, et al. Executive summary of stroke statistics in Korea 2018: a report from the Epidemiology Research Council of the Korean Stroke Society. J Stroke. 2019. 21:42–59.

6. Lau LH., Lew J., Borschmann K., Thijs V., Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. J Diabetes Investig. 2019. 10:780–92.

7. Rawshani A., Rawshani A., Franzén S., Sattar N., Eliasson B., Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018. 379:633–44.

8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. 352:837–53.

9. Diabetes Control and Complications Trial Research Group. Nathan DM., Genuth S., Lachin J., Cleary P., Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–86.

10. Holman RR., Paul SK., Bethel MA., Matthews DR., Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. 359:1577–89.

11. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC., Miller ME., Byington RP., Goff DC Jr., Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008. 358:2545–59.

12. ADVANCE Collaborative Group. Patel A., MacMahon S., Chalmers J., Neal B., Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008. 358:2560–72.

13. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven PD, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009. 360:129–39.

14. Laiteerapong N., Ham SA., Gao Y., Moffet HH., Liu JY., Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019. 42:416–26.

15. Kim MK., Ko SH., Kim BY., Kang ES., Noh J., Kim SK, et al. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019. 43:398–406.

16. Hankey GJ., Anderson NE., Ting RD., Veillard AS., Romo M., Wosik M, et al. Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study. J Neurol Neurosurg Psychiatry. 2013. 84:281–7.

17. Bellolio MF., Gilmore RM., Ganti L. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev. 2014. (1):CD005346.

18. Johnston KC., Bruno A., Pauls Q., Hall CE., Barrett KM., Barsan W, et al. Neurological Emergencies Treatment Trials Network and the SHINE Trial Investigators. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. JAMA. 2019. 322:326–35.

19. Jauch EC., Saver JL., Adams HP Jr., Bruno A., Connors JJ., Demaerschalk BM, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013. 44:870–947.

20. Dormandy JA., Charbonnel B., Eckland DJ., Erdmann E., Massi-Benedetti M., Moules IK, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005. 366:1279–89.

21. Wilcox R., Bousser MG., Betteridge DJ., Schernthaner G., Pirags V., Kupfer S, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007. 38:865–73.

22. Kernan WN., Viscoli CM., Furie KL., Young LH., Inzucchi SE., Gorman M, et al. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016. 374:1321–31.

23. Marso SP., Bain SC., Consoli A., Eliaschewitz FG., Jódar E., Leiter LA, et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016. 375:1834–44.

24. Gerstein HC., Colhoun HM., Dagenais GR., Diaz R., Lakshmanan M., Pais P, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019. 394:121–30.

25. Marso SP., Daniels GH., Brown-Frandsen K., Kristensen P., Mann JF., Nauck MA, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016. 375:311–22.

26. Hernandez AF., Green JB., Janmohamed S., D'Agostino RB Sr., Granger CB., Jones NP, et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018. 392:1519–29.

27. Husain M., Birkenfeld AL., Donsmark M., Dungan K., Eliaschewitz FG., Franco DR, et al. PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019. 381:841–51.

28. Pfeffer MA., Claggett B., Diaz R., Dickstein K., Gerstein HC., Køber LV, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015. 373:2247–57.

29. Holman RR., Bethel MA., Mentz RJ., Thompson VP., Lokhnygina Y., Buse JB, et al. EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017. 377:1228–39.

30. Scirica BM., Bhatt DL., Braunwald E., Steg PG., Davidson J., Hirshberg B, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013. 369:1317–26.

31. White WB., Cannon CP., Heller SR., Nissen SE., Bergenstal RM., Bakris GL, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013. 369:1327–35.

32. Green JB., Bethel MA., Armstrong PW., Buse JB., Engel SS., Garg J, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015. 373:232–42.

33. Rosenstock J., Perkovic V., Johansen OE., Cooper ME., Kahn SE., Marx N, et al. CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019. 321:69–79.

34. Zinman B., Wanner C., Lachin JM., Fitchett D., Bluhmki E., Hantel S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015. 373:2117–28.

35. Neal B., Perkovic V., Mahaffey KW., de Zeeuw D., Fulcher G., Erondu N, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. 377:644–57.

36. Wiviott SD., Raz I., Bonaca MP., Mosenzon O., Kato ET., Cahn A, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019. 380:347–57.

37. Cannon CP., Pratley R., Dagogo-Jack S., Mancuso J., Huyck S., Masiukiewicz U, et al. VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020. 383:1425–35.

38. ORIGIN Trial Investigators. Gerstein HC., Bosch J., Dagenais GR., Díaz R., Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012. 367:319–28.

39. Marso SP., McGuire DK., Zinman B., Poulter NR., Emerson SS., Pieber TR, et al. DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017. 377:723–32.

40. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998. 317:703–13.

41. ACCORD Study Group. Cushman WC., Evans GW., Byington RP., Goff DC Jr., Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010. 362:1575–85.

42. Bangalore S., Kumar S., Lobach I., Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011. 123:2799–810.

43. Colhoun HM., Betteridge DJ., Durrington PN., Hitman GA., Neil HA., Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004. 364:685–96.

44. Keech A., Colquhoun D., Best J., Kirby A., Simes RJ., Hunt D, et al. LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003. 26:2713–21.

45. American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021. 44(Suppl 1):S125–50.

46. Mach F., Baigent C., Catapano AL., Koskinas KC., Casula M., Badimon L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020. 41:111–88.

47. Antithrombotic Trialists' (ATT) Collaboration. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009. 373:1849–60.

48. Saito Y., Okada S., Ogawa H., Soejima H., Sakuma M., Nakayama M, et al. JPAD Trial Investigators. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation. 2017. 135:659–70.

49. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996. 348:1329–39.

50. Wang Y., Wang Y., Zhao X., Liu L., Wang D., Wang C, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013. 369:11–9.